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http:WHAT THIS PAPER ADDS
In patients with enlarging aneurysms of unknown origin after endovascular aneurysm repair, magnetic reso-
nance imaging (MRI) with a weak albumin binding contrast agent has additional diagnostic value for both the
detection and determination of the origin of the endoleak. Therefore, MRI should be considered in patients with
aneurysm growth of unknown origin in cases where computed tomography angiography imaging does not reveal
a clear cause.Objectives/Background: To examine the additional diagnostic value of magnetic resonance imaging (MRI) after
administration of a weak albumin binding contrast agent in post-endovascular aneurysm repair (EVAR) patients
with aneurysm growth with no or uncertain endoleak after computed tomography angiography (CTA).
Methods: This was a prospective diagnostic cross sectional study carried out between April 2011 and August
2013. MRI was performed in all patients with aneurysm growth 5 mm after EVAR implantation and no or
uncertain endoleak on CTA, or the inability, on CTA, to identify the source of a visible endoleak. All MRI scans
were performed on a 1.5 T clinical MRI scanner after administration of a weak albumin binding contrast agent.
The presence of endoleaks was assessed by visually comparing pre- and post-contrast T1-weighted images with
fat suppression. Post-contrast images were acquired 5 and 15 minutes after contrast administration.
Results: Twenty-nine patients (26 men; 90%) with a median age of 74 years (interquartile range [IQR] 67e76)
were included. The median interval between EVAR and MRI was 39 months (IQR 20e50). The median increase in
maximum aneurysm diameter during total follow up after EVAR was 11 mm (IQR 6e17). At CTA, 16 patients
(55%) had no detectable endoleak, ﬁve patients (17%) had suspected but uncertain endoleak, and eight patients
had a deﬁnite endoleak (28%). On the post-contrast MRI images, endoleak was observed in 24 patients (83%). In
all patients with uncertain endoleak on CTA, endoleak was detected with MRI. For type II endoleaks, feeding
vessels were detected in 22/23 patients (96%) and these were all, except one, lumbar arteries.
Conclusion: In patients with enlarging aneurysms of unknown origin after EVAR, MRI with a weak albumin
binding contrast agent has additional value for both the detection and determination of the origin of the
endoleak.
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Endovascular aneurysm repair (EVAR) is a suitable alternative
for conventional open abdominal aortic aneurysm (AAA)
repair. However, a common complication after EVAR is the
occurrence of endoleak. Although the incidence of different
types of endoleaks reported in the literature varies, and
depends on patient selection and on the type of stent graft
used, it is assumed type I endoleaks occur in 0e10% of pa-
tients and the incidence of type II endoleaks ranges from 10%
to 25%.1 Type III and type IV endoleaks are less common with
the use of newer generation stent grafts.1
Table 1. Magnetic resonance imaging (MRI) compatibility
(modiﬁed from van der Laan et al.)27
MRI compatible grafts
(nitinol/platinum/gold)
MRI incompatible grafts
(stainless steel/elgiloy)
Aneurx (nitinol/platinum) Zenith (stainless steel/gold)
Talent (nitinol) Lifepath (elgiloy)
Excluder (nitinol/gold) Ancure (elgiloy/platinum)
Endurant (nitinol)
Quantum LP (nitinol/tantalum
Anaconda (nitinol)
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consider endotension as the ﬁfth type of endoleak. Endo-
tension is deﬁned as continued growth of the aneurysm sac
after EVAR treatment without endoleak detected on
computed tomography angiography (CTA).2 Recent results
from a study investigating a multicenter patient population
showed that the 5 year post EVAR rate of AAA sac
enlargement in a certain cohort of patients was 41%.3
Aneurysm sac enlargement after EVAR may result in
rupture with severe associated comorbidity and mortality.
Optimal non-invasive imaging is therefore crucial to
detect the exact cause of aneurysm sac enlargement. CTA is
the preferred imaging modality for the detection of endo-
leaks after EVAR but may miss endoleaks. The detection of
these occult endoleaks is crucial in patients with aneurysm
growth because in these patients an intervention may be
considered according to guidelines.4,5 This ﬁnding has
sparked the search for alternative methods to detect
endoleaks after EVAR implantation. One such method,
contrast enhanced magnetic resonance imaging (CE-MRI),
holds promise for this purpose, as has been shown in a
recent meta-analysis, which found that CE-MRI is more
sensitive than CTA for the detection of endoleaks, especially
for slow ﬂow/type II endoleaks.6 This is important because
type II endoleaks are not always harmless as they may
result in adverse outcome after EVAR including rupture.7,8
Besides standard gadolinium contrast agents, albumin
binding contrast agents can be used for MRI examinations
aimed at the detection of endoleaks. The expected advan-
tages of albumin binding contrast agents compared with
standard gadolinium chelates are prolonged intravascular
presence of the contrast agent resulting in a prolonged T1
relaxation rate.9e11 In Europe, the European Medicines
Agency withdrew the license to market the strong albumin
binding contrast agent gadofosveset trisodium (Ablavar;
Lantheus Medical Imaging, Billerica, MA, USA) in late 2011,
and this agent is no longer available for clinical use.12
Therefore, the aim of this study was to investigate if a
weak albumin binding contrast agent could identify addi-
tional endoleaks in the study population. The purpose of
this study was to examine the additional value of MRI with
a weak albumin binding contrast agent for the detection of
endoleaks in post EVAR patients with aneurysm growth.
MATERIALS AND METHODS
Patient selection
Patients were eligible for inclusion if they fulﬁlled the
following criteria: (1) aneurysm growth  5 mm after EVAR
of an infrarenal aneurysm; (2) treated with a MR compat-
ible endograft (Table 1); and (3) no or uncertain endoleak
on CTA, or the inability to identify the source of a visible
endoleak on CTA. Patients between April 2011 and August
2013 were included, regardless of the date of the initial
EVAR. Patients were excluded if they had MRI speciﬁc
contraindications (i.e., claustrophobia or incompatible im-
plants) or contraindications for the administration of gad-
olinium (renal impairment, deﬁned as glomerular ﬁltrationrate  30 mL/minute). The study protocol was reviewed by
the local institutional review board. The ethics committee
waived the need for informed consent, as CE-MRI for
endoleak detection is standard clinical practice in the au-
thors’ institution in cases where patients fulﬁlled one of the
criteria listed above.
CTA
During routine CTA follow up after EVAR, arterial and
delayed phase CTA were performed on a 256 slice CT
scanner (Philips Medical Systems, Best, The Netherlands)
with a standardized acquisition protocol (Supplementary
Material Appendix S1).
MRI
All MRI scans were performed on a 1.5 T clinical scanner
(Ingenia, software release 4.2; Philips Healthcare) after
administration of a weak albumin binding contrast agent. A
single dose of 0.1 mmoL/kg gadobenate dimeglumine
(Multihance; Bracco, Milan, Italy) was administrated at a
rate of 1.0 mL/second followed by a 30 mL saline ﬂush at a
rate of 1.0 mL/second. A 28 element phased array radio-
frequency body coil was used for signal reception. A
regional saturation slab was located on the anterior
abdominal wall to prevent breathing artefacts. Precontrast
T1 weighted fat saturated and post-contrast T1 weighted fat
saturated images were acquired 5 and 15 minutes after
contrast administration with the following acquisition pa-
rameters: TR/TE/a 5.4 ms/2.6 ms/10; slice thickness 2 mm;
ﬁeld of view 385  300 mm2; acquisition matrix
1.5  1.5  1.5 mm; acquisition time 21 seconds.
Image analysis
The presence of endoleaks was assessed by comparing pre-
and post-contrast T1 weighted fat saturated images. Both
the early (after 5 minutes) and late (after 15 minutes) post-
contrast T1 weighted fat saturated images were used during
the assessment. The presence of endoleak was deﬁned as a
high intensity signal inside the aneurysm sac on post-
contrast images not present on pre-contrast images.10 The
identiﬁcation of post-contrast high signal intensity dorsally
(lumbar type II endoleak) and ventrally (inferior mesenteric
artery [IMA] type II endoleak) in direct connection with the
aneurysm sac indicates the presence of a type II endoleak.
Furthermore, the presence of prominent lumbar arteries
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suspected presence of a type II endoleak. All CTA and MRI
scans were assessed by two experienced cardiovascular
radiologists blinded to the ﬁndings at CTA and MRI,
respectively. After the initial assessment, the MRI scans
were discussed in a multidisciplinary meeting with inter-
ventional radiologists and vascular surgeons for ﬁnal clas-
siﬁcation and to discuss treatment implications. Based on
the multidisciplinary consensus meeting, patients were
qualiﬁed as having “endoleak”, “uncertain endoleak”, “no
endoleak”, or “non-assessable images”.
Data presentation
Discrete variables are shown as number and percentages.
Continuous variables are expressed as means with SDs or
median values with interquartile range (IQR), depending of
the normality of the data distribution. Differences in
aneurysm sac diameter were assessed by non-parametric
testing. p-Values< .05 were considered signiﬁcant, and all
analyses were performed with SPSS statistics (version 20;
IBM, Armonk, NY, USA)
RESULTS
Baseline characteristics
Thirty patients underwent MRI evaluation. One patient was
excluded because of the presence of a stainless steel
extension cuff that resulted in a non-diagnostic MRI ex-
amination. This study demonstrates that stent grafts made
of nitinol are suitable for MRI evaluation (Table 1). In total,
29 patients (26 men; 90%) were included; the median age
of the patients at the time of EVAR was 74 years (IQR 67e
76). All baseline characteristics are listed in Table 2. Twenty-
one patients (72%) had no or uncertain endoleak on CTA
examination prior to the MRI examination.
MRI analysis
Twenty-nine MRI examinations were included in the
analysis. All results are presented in Table 3. Endoleak was
observed in 24/29 patients (83%) on the post-contrast
MRI images. These endoleaks were all visible on both
the early and the late post-contrast T1 weighted fatTable 2. Baseline characteristics.
Parameter
Pre-operative aneurysm diameter (mm) 63 (56e73)
Aneurysm diameter at last CTA (mm) 78 (67e86)
Aneurysm growth (mm) 11 (7e16)
Time between EVAR and MRI (mo) 39 (20e50)
Time between last CTA and MRI (d) 32 (23e50)
Reason for inclusion, n (%)
Growth with no endoleak on CTA 16 (55)
Growth with uncertain endoleak on CTA 5 (17)
Growth with endoleak on CTA 8 (28)
Note. Values are presented as median (interquartile range) unless
otherwise indicated. CTA ¼ computed tomography angiography;
EVAR ¼ endovascular aneurysm repair; MRI ¼ magnetic
resonance imaging.saturated images. Three patients had no endoleak (10%)
and two patients (7%) had an uncertain type III/IV endo-
leak on MRI examination. In the group of patients with no
endoleak (n ¼ 3), (1) patient 13 had no imaging follow up
at patient request, and this patient died 2.5 years after the
MRI examination because of respiratory insufﬁciency
(general practitioner [GP] registration); (2) patient 21
underwent a re-intervention with both proximal and distal
extension of the EVAR with branching of the renal arteries,
and 2 years after re-intervention, the aneurysm diameter
was stable without visible endoleak; and (3) patient 26
rejected further imaging follow up because of progressive
dementia, and this patient was still alive 1 year after
magnetic resonance angiography examination (GP
registration).
The two patients with uncertain endoleak were treated
by conservative management and follow up imaging: pa-
tient 17 had imaging follow up (8 months) with duplex ul-
trasound and CTA, which showed a stable aneurysm
diameter and persistent endoleak; patient 22 had imaging
follow up (1.5 years) with duplex ultrasound and CTA, which
showed a stable aneurysm diameter and no visible
endoleak.
Twenty-three of 24 patients (96%) with an endoleak seen
on MRI had a type II endoleak (Fig. 1). The remaining pa-
tient had a type III endoleak (4%).
Eight of 23 patients (35%) with a type II endoleak
detected by MRI also had a type II endoleak on delayed
phase CT imaging (Fig. 2). These eight patients were
referred for MRI imaging because the referring surgeon was
unsure whether or not an endoleak was truly present, or
suspected a more extensive endoleak than was found with
CTA. Furthermore, these eight patients were included for
validation of the MRI ﬁndings. On both MRI and CTA, all
eight patients demonstrated type II endoleaks at the same
location. Furthermore, MRI had complementary value in
seven of eight patients (88%) by visualizing more feeding
lumbar arteries (n ¼ 3) (Fig. 3), by improving the visuali-
zation of the extent of the endoleak (n ¼ 3), and by
detection of an IMA endoleak (n ¼ 1) and an additional
type III endoleak (n ¼ 1). In one patient, MRI detected both
additional feeding arteries and an additional type III endo-
leak. Fig. 1 shows a patient with no endoleak on CTA and a
type II endoleak caused by a lumbar feeding artery visual-
ized by MRI.Endoleak treatment
Twenty-one patients (72%) underwent a secondary inter-
vention after the MRI examination demonstrated an
endoleak (Table 4). All ﬁve patients with no or unclear
endoleak on MRI were kept under surveillance and expec-
tant management was followed. Three patients did not
undergo an intervention, although an endoleak was found
on MRI. Patient 5 was deceased (cause of death remained
unknown). Patient 27 had a solitary type III endoleak but
was kept under surveillance as the aneurysm growth was
limited (5 mm) and remained stable during follow up.
Table 3. Results of endoleak detection by magnetic resonance imaging (MRI).
Patient FU time between
EVAR and MRI (mo)
Growth since
EVAR (mm)
Endoleak detected
by CTA
Endoleak detected
by MRI
Endoleak type
on MRI
Feeding artery visible
1 13 7 Uncertain Yes II L4 both sides
2 37 7 No Yes II L4 left
3 45 15 No Yes II L3 right
4 12 13 No Yes II Unclear
5 120 46 Uncertain Yes II/uncertain III L4 both sides
6 19 11 Yes Yes II IMA/L4 right
7 36 6 No Yes II/III S1 left
8 47 8 No Yes II L4 right
9 44 6 Yes Yes II L4 both sides
10 40 15 Yes Yes II IMA
11 3 5 Yes Yes II IMA/L3 right
12 25 12 Yes Yes II L4 both sides
13 22 7 No No e e
14 13 7 Yes Yes II L4 both sides
15 69 8 Uncertain Yes II L2 right
16 31 10 Uncertain Yes II/uncertain III/IV Multiple lumbar
17 64 5 No Uncertain Uncertain III/IV e
18 21 12 Yes Yes II IMA/L4eL5 both sides
19 38 6 Uncertain Yes II L3 both sides
20 75 6 No Yes II L3eL4 both sides
21 11 17 No No e e
22 46 9 No Uncertain Uncertain III/IV e
23 53 25 No Yes II IMA/multiple lumbar
24 40 12 No Yes II L4 both sides
25 14 22 Yes Yes II/III Multiple lumbar
26 47 20 No No e e
27 39 5 No Yes III e
28 82 27 No Yes II Multiple lumbar
29 58 16 No Yes II L4 both sides
Note. FU ¼ follow up; EVAR ¼ endovascular aneurysm repair; CTA ¼ computed tomography angiography; IMA ¼ inferior mesenteric
artery.
334 J. Habets et al.Patient 29 refused treatment and the aneurysm diameter
remained stable during follow up.
Correlation with digital subtraction angiography
For 20 of the 21 patients digital subtraction angiography
(DSA) with attempted embolization was performed. This
resulted in 19 of 20 conﬁrmed endoleaks and embolization
attempts (95%). In patient 7, MRI demonstrated contrast
around the iliac left limb, suspected to be a combined type
II/III endoleak. However, DSA could not prove the presence
of an endoleak and follow up CT(A) imaging and re-
operation demonstrated a large para-iliac hematoma.
The remaining patient (patient 25) of the 21 treated
patients demonstrated no endoleak on DSA but received a
distal limb extension because of short sealing length and
further aneurysm sac growth.
During 19 embolization procedures, super selective
embolization of the lumbar artery at the level of the
endoleak was attempted. However, the ilio-lumbar artery
was coiled in three patients (16%) as the lumbar artery
could not be reached. These interventions were considered
to be technically successful because no ﬂow in the involved
lumbar arteries was seen after coil placement. Embolization
was technically not successful in two patients (10%).
Overall, 11 patients (52%) required one or more addi-
tional procedures after the initial intervention.In 16 of 21 patients (76%) a MRI was performed after the
intervention. However, for clinical reasons and patient
convenience this was mostly limited to one MRI scan post-
intervention. During further follow up (median 21.3
months; IQR 13.3e27.8) CTA was used in most patients to
monitor aneurysm growth. During follow up after the initial
secondary intervention up to the last available imaging,
aneurysm diameter remained stable or decreased ( 5 mm)
in 14 patients and increased ( 5 mm) in four. Three of
these four patients are scheduled for additional in-
terventions (two additional embolizations and one fenes-
trated extension cuff). One patient refused further
treatment because of progressive cognitive and physical
deterioration. No follow up imaging data were available in
two patients (patient 2 and 20).DISCUSSION
The principal ﬁnding of this study is that MRI after admin-
istration of a weak albumin binding contrast agent
(gadobenate dimeglumine) results in the unmasking of
previously unknown endoleaks in patients with AAA growth
post EVAR. In 16 of 24 (67%) patients an additional endo-
leak was detected, mainly type II caused by lumbar feeding
arteries. The detection of these occult endoleaks is clinically
Figure 1. A patient after endovascular aneurysm repair with continued aneurysm growth with no endoleak on (A) arterial phase and
(B) delayed phase computed tomography angiography, and (C) pre-contrast T1 weighted fat suppressed images. (D) The post-contrast
T1 weighted fat suppressed images clearly demonstrated a type II endoleak originating from a lumbar artery. Furthermore, on the
pre-contrast images a high signal is seen around the stent graft limbs, representing so called wet thrombus.
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growth post EVAR because it may have treatment implica-
tions according to the Society for Vascular Surgery/Euro-
pean Society for Vascular Surgery guidelines.4,5
A previous study by Cornelissen et al. showed compara-
ble results.10 Cornelissen et al. discussed 12 patients with
non-shrinking aneurysms after EVAR and no evidence of
endoleak on CTA.10 In six of 11 (55%) patients additional
endoleaks were detected by MRI using the strong albumin
binding contrast agent gadofosveset trisodium (Ablavar;
Lantheus Medical Imaging, Billerica, MA, USA).10 As this
contrast agent is available exclusively in the USA, the aim of
the present study was to investigate the value of another
albumin binding contrast agent. The contrast agent used in
the present study, gadobenate dimeglumine, was previously
used for endoleak detection by Alerci et al.9 The study by
Alerci et al. showed that MRI with this albumin binding
contrast agent was superior to CTA for endoleak detection,
mainly for type II endoleaks.9 In contrast to Alerci et al.,9
who analyzed a series of patients under follow up after
EVAR, the present study investigated a different study
population by including only patients with aneurysm
growth after EVAR. This inclusion criterion was chosen as a
detected endoleak could have consequences for treatment
strategy, according to the guidelines as stated earlier, only
for this group of patients.
A possible explanation for continued aneurysm expansion
after EVAR without detectable endoleak is that endotensionmight actually consist of low ﬂow type II endoleaks below
the detection limit of CTA.13 Theoretically, MRI with albu-
min binding contrast agent would improve endoleak
detection because of the superior soft tissue contrast of
MRI imaging and the prolonged intravascular presence of
an albumin binding contrast agent with high T1 relaxation
rate. Given the results of the present study, it seems a
credible theory given a type II endoleak was found in the
vast majority of patients. However, three of 29 (10%) pa-
tients had no detectable endoleak on MRI. This ﬁnding
necessitates consideration of other theories about the
origin of endotension. A potential role is played by the
intraluminal thrombus. Pressure may remain high in the
excluded aneurysm sac owing to transmission of the pres-
sure through the intraluminal thrombus around graft
attachment zones or through the permeable graft mate-
rial.13e15 In addition, it is known that presence of intra-
luminal thrombus is associated with degeneration of the
underlying vessel wall,16,17 although the relationship of
intraluminal thrombus with aneurysm sac growth and
rupture risk remains unclear.
The described protocol in combination with the used
contrast agent performed reasonably well for the determi-
nation of the origin of endoleaks. Detection of feeding
vessels might improve the guidance of super selective
embolization, as type II endoleaks are often fed by multiple
vessels.18 However, the guidance of the treatment strategy
was not the purpose of this study. Moreover, the
Figure 2. A patient after endovascular aneurysm repair with continued aneurysm growth with a certain endoleak on (A) the arterial phase
and more obvious on (B) the delayed phase computed tomography angiography. (CeE) The (E) post-contrast T1 weighted fat suppressed
images compared with (C) the T1 weighted fat suppressed images revealed a type II endoleak, which had (D, E) multiple feeding lumbar
arteries (arrows). (D) Slice located more cranially and illustrates higher located lumbar feeding arteries (arrows).
336 J. Habets et al.visualization of feeding lumbar arteries or IMA in patients
with type II endoleak and the visualization of the extent of
the endoleak was improved. Gadobenate dimeglumine
provides improved vascular enhancement in more distal
vessels of the peripheral circulation compared with stan-
dard extracellular gadolinium chelates.19 Furthermore, in
pedal arteries it was proven that MRI with gadobenate
dimeglumine was able to visualize signiﬁcantly more patent
vessels than selective digital subtraction angiography.20 A
recent meta-analysis demonstrated that albumin binding
contrast agents may have additional diagnostic value
compared with standard gadolinium chelates in the detec-
tion of endoleaks. However, heterogeneity and insufﬁcient
power hamper deﬁnitive conclusions. Both standard gado-
linium chelates as albumin binding contrast agents are su-
perior to CTA, including delayed-phase imaging, for
endoleak detection.6 Further studies with albumin binding
contrast agents are required to determine if albumin
binding contrast agents are superior to conventional
extracellular gadolinium for the detection of endoleaks.
The clinical signiﬁcance of additionally detected type II
endoleaks in patients with aneurysm growth remains to beestablished. Sarac et al. described long-term follow up re-
sults after embolization.21 After 5 years, freedom from
explant was 88.8%, freedom from second embolization
procedure was 75.8%, and freedom from continued sac
growth was just 43.7%.21 At present, international guide-
lines recommend that percutaneous intervention has to be
considered in patients with continued expansion of the
treated aneurysm because of the increased rupture risk
over patients without endoleak.4,5 However, for the most
commonly used techniques, transarterial and translumbar
embolization, technical success rates appear to be good;
however, according to the current literature, clinical success
varies widely.22e25 Despite intervention not being success-
ful at the ﬁrst attempt in some patients, further aneurysm
growth was ﬁnally arrested in 15 of 21 patients (71%)
during follow up. This study focuses on the detection of
endoleak rather than treatment in patients with aneurysm
growth with no or uncertain endoleak after CTA. However,
the results also show that the clinical success of secondary
interventions for type II endoleak is moderate. Further
study, preferably in the form a prospective randomized
clinical trial, is needed to investigate the effect on outcome.
Figure 3. A patient after endovascular aneurysm repair with continued aneurysm growth with no endoleak on (A) the arterial phase and (B)
an uncertain endoleak (arrow) on the delayed phase computed tomography angiography. (C, D) The (D) post-contrast T1 weighted fat
suppressed images compared with (C) the T1 weighted fat suppressed images revealed an obvious type II endoleak (*).
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population was investigated as growth after EVAR with or
without uncertain endoleak on CTA is uncommon in the
endovascularly treated population.25 In addition, the time
between CTA and MRI could have had some inﬂuence. With
a delay between CTA and MRI it is theoretically possible
that the endoleak arose in the intervening interval,
although this is unlikely.
Second, an ideal reference standard for validation of the
endoleaks detected by MRI is lacking. In the literature, it is
known that DSA can miss endoleaks and, because of the
invasive character of the procedure, DSA was only per-
formed in patients (72%) for treatment purposes. Therefore,
sensitivity and speciﬁcity calculations based on DSA cannot
be performed in a reliable manner because of veriﬁcation
bias (not all patients with a CTA and MRI examination un-
derwent DSA). This notwithstanding, it is important to note
that in the patients in whom MRI showed an endoleak,
there was also endoleak seen on CTA. There were no cases
where MRI did not show endoleak and CTA did.
In clinical practice, the cost of the contrast agent can play
a role by choosing not only a conventional gadolinium
chelate but also an albumin binding contrast agent.However, a previous meta-analysis demonstrated that both
type of contrast agents improve endoleak detection
compared with CTA.6 Besides the cost, the availability of
contrast agents can be an issue. In Europe, the stronger
albumin binding contrast gadofosveset trisodium (Ablavar;
Lantheus Medical Imaging, Billerica, MA, USA) is no longer
available. However, the current research was carried out
with a contrast agent that is available nearly everywhere
worldwide, gadobenate dimeglumine (MultiHance; Bracco),
which exhibits weak protein binding.
Patient habitus may play a role in the detection of
endoleaks. In this study, we performed the MRI examina-
tions on a wide-bore 1.5-T MRI system and patient habitus
did not hamper the assessment of the examinations. Data
analysis based on patient habitus or body mass index could
not be performed in the small patient population with
sufﬁcient power, and this study was also not powered to
analyze the effect of patient anatomy.
In the opinion of the authors of the present study,
repeating the CTA would probably not improve the detec-
tion of endoleaks signiﬁcantly. Based on a previous pub-
lished meta-analysis,6 and the results presented herein, MRI
is superior in the detection of slow ﬂow endoleaks because
Table 4. Treatment results.
Patient Initial treatment MRI
conﬁrmed
Technical
success
Additional interventions Last imaging FU
1 Super selective embolization
(AII) L4 multiple branches
Yes Yes Ligation lumbar artery by median laparotomy
because of further growth and persisting endoleak
Decreased aneurysm diameter
2 Super selective embolization
(AII) L4 left
Yes Yes Relining distal limb and embolization because of
persisting endoleak and further growth
No imaging FU available since last intervention
3 Super selective embolization
(AII) L3eL4 right
Yes Yes Fenestrated extension cuff because of short distal
sealing zone and further growth
Aneurysm diameter remained stable
4 Super selective embolization
(AII) L3 left
Yes No Ligation lumbar artery by median laparotomy
because of further growth
Decreased aneurysm diameter
5 No intervention No imaging FU available
6 Super selective embolization (AII)
þ direct embolization of the
aneurysm sac
Yes Yes Increased aneurysm diameter
7 No endoleak during DSA No Aneurysm diameter remained stable
8 Super selective embolization with
CT expert guide using histoacryl
Yes Yes DSA with successful embolization of lumbar arteries
and later during FU conversion to open procedure
because of further growth and persisting endoleak
Stable disease after open conversion
9 Super selective embolization (AII) Yes Yes Decreased aneurysm diameter
10 Super embolization IMA Yes Yes Increased aneurysm diameter
11 Super embolization IMA Yes Yes Aneurysm diameter remained stable
12 Super selective embolization (AII) Yes Yes Aneurysm diameter remained stable
13 e No imaging follow up available
14 Supers elective embolization (AII)
þ histoacryl in the aneurysm sac
Yes Yes Second successful procedure: super selective
embolization þ direct embolization of the aneurysm sac
Aneurysm diameter remained stable
15 Super selective embolization with
expert CT guidance with histoacryl
Yes Yes Direct embolization of the aneurysm sac Aneurysm diameter remained stable
16 Super selective embolization (AII) Yes Yes Increased aneurysm diameter
17 e Aneurysm diameter remained stable
18 Super selective embolization (AII) Yes Yes Aneurysm diameter remained stable
19 Super selective embolization (AII) Yes Yes Decreased aneurysm diameter
20 Super selective embolization (AII) Yes Yes No imaging FU available since last intervention
(alive 2 years after MRA examination)
21 e No imaging FU available
22 e Aneurysm diameter remained stable
23 Super selective embolization (AII) Yes Yes Direct embolization of the aneurysm sac with histoacryl Aneurysm diameter remained stable
24 Super selective embolization Yes No Super selective embolization þ direct embolization
of the aneurysm sac
Increased aneurysm diameter treated ﬁnally with
proximal extension because of type I endoleak
25 Distal limb extension Yes Proximal extension cuff because of potential type IA
endoleak
Aneurysm diameter remained stable
26 e Patient refused further treatment and FU
27 No intervention Aneurysm diameter remained stable
28 Selective embolization (AII) Yes Yes direct embolization of the aneurysm sac with histoacryl Aneurysm diameter remained stable
29 No intervention e e Aneurysm diameter remained stable
Note. MRI ¼ magnetic resonance imaging; FU ¼ follow up; AII ¼ internal iliac artery; DSA ¼ digital subtraction angiography; CT ¼ computed tomography; IMA ¼ inferior mesenteric artery;
MRA ¼ magnetic resonance angiography.
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Enlarging Aneurysm after EVAR 339of the superior soft tissue contrast of MRI compared with
CTA. Furthermore, the weak albumin binding contrast agent
used in this study will increase the T1 relaxivity and
therefore improve the contrast enhancement, which may
improve endoleak visualization. Furthermore, the longer
intravascular presence of albumin binding contrast agents
may improve the visualization of slow ﬂow endoleaks.
Finally, compared with CTA, contrast enhanced ultra-
sound (CEUS) is a highly accurate diagnostic technique
(sensitivity 98%, speciﬁcity 88%) with which to evaluate
patients with suspected endoleaks post EVAR.26 The ad-
vantages of CEUS compared with MRI are the relative low
costs and availability. MRI was chosen here as an index test
because of the authors’ long-standing experience with this
technique. Future studies with CEUS in this patient popu-
lation to compare these ﬁndings with MRI and to evaluate
the value of CEUS in this speciﬁc population will be
interesting.
In conclusion, aneurysm sac enlargement is an occa-
sionally encountered but clinically relevant phenomenon in
patients after EVAR. When multiphase CTA is not able to
detect an endoleak or is inconclusive in this group of pa-
tients, an additional MRI examination with an albumin
binding contrast agent should be considered.
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